VTRS · Healthcare

Viatris Inc

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window

News · 2026-08-07

• Guidance / OutlookImportance 62 · Surprise 68
  Viatris raised the midpoints of all 2026 financial guidance metrics after reporting second-quarter results on August 6, 2026. Third-party reporting said the company raised its adjusted earnings and sales outlook, with…
• Generic Pricing PressureImportance 38 · Surprise 24
  Viatris faces ongoing pricing pressure across the generics market, particularly in developed markets. Generics in developed markets are experiencing product erosion, which is pressuring revenue and margins. Viatris is…
• Nashik Supply DisruptionImportance 37 · Surprise 42
  Viatris reported supply disruptions at its Nashik facility in India. The disruption is expected to temper growth in the second half of 2026. The news indicates that manufacturing-site continuity remains a risk to…
• Acquisition / Partnership / DivestitureImportance 34 · Surprise 42
  Viatris agreed to sell the global rights to Tyrvaya, its varenicline solution nasal spray for dry eye disease, to Harrow Inc. The transaction includes $30 million of upfront cash and up to $70 million in contingent…

10-Q · 2026-08-06

• Other Income (Expense), NetImportance 77 · Surprise 82
  Second-quarter 2026 other income was $50.4 million, compared with $333.5 million of other expense in the prior-year quarter, a favorable change of $383.9 million. The improvement primarily reflected a $56.3 million…
• Acquisition / Partnership / DivestitureImportance 71 · Surprise 60
  Viatris sold all of its preferred shares in Biocon Biologics under agreements signed in December 2025 for total consideration of $815.0 million, consisting of $400.0 million in cash and $415.0 million of newly issued…
• Income Tax Rate ChangesImportance 65 · Surprise 82
  Viatris recorded a $54.8 million income tax provision in the second quarter of 2026, compared with a $212.5 million tax benefit in the prior-year quarter, a $267.3 million unfavorable change. The 2026 provision was…
• Headcount / RestructuringImportance 64 · Surprise 42
  Viatris expects its 2026 enterprise-wide strategic review restructuring program to reduce its global workforce by up to approximately 10% and to be implemented primarily over three years. The program is expected to…
• Interest Rate and Refinancing ExposureImportance 64 · Surprise 42
  During the six months ended June 30, 2026, Viatris repaid approximately $1.675 billion of 3.950% Senior Notes at maturity and issued approximately $752.8 million of 4.250% Euro Senior Notes due 2033. The Company also…
• Accrued Legal and RegulatoryImportance 64 · Surprise 42
  Viatris had approximately $453 million accrued for legal contingencies at June 30, 2026, covering disputes, governmental and regulatory inquiries, investigations, tax proceedings, and litigation in the United States…
• Distribution ChannelsImportance 60 · Surprise 40
  Greater China constant-currency net sales increased 17% in the first six months of 2026 and 16% in the second quarter. Growth was broad-based across multiple channels, specifically including e-commerce and retail.…
• Revenue Performance and MixImportance 59 · Surprise 32
  Second-quarter 2026 total revenues increased 5% year over year to $3.76 billion from $3.58 billion, while constant-currency revenues rose 4% to $3.71 billion. Greater China net sales increased 21% to $713.8 million, or…
• Research and Development ExpenseImportance 54 · Surprise 40
  Second-quarter 2026 R&D expense increased $29.5 million, or 13%, to $248.3 million from $218.8 million. Six-month R&D expense increased $56.1 million, or 13%, to $496.9 million from $440.8 million. The increase in both…
• Geographic Market CommentaryImportance 54 · Surprise 40
  Greater China was the strongest growth market, with constant-currency net sales up 17% in the first six months and 16% in the second quarter, driven by broad-based growth across multiple channels. Developed Markets…
• Gross Margin DriversImportance 49 · Surprise 32
  Second-quarter 2026 gross profit increased $123.6 million to $1.46 billion, and reported gross margin expanded to 39% from 37%, primarily because of product mix. Six-month gross profit increased $119.6 million to $2.61…
• Liquidity and Debt PositionImportance 49 · Surprise 6
  Viatris reported $886.5 million of cash and cash equivalents at June 30, 2026 and $770.1 million of operating cash flow for the six months then ended. The Company expects available cash, operating cash generation, and…
• Manufacturing and Supply DisruptionsImportance 47 · Surprise 60
  An FDA warning letter and import alert affecting Viatris’ Indore, India facility continue to restrict 11 products from entering the U.S., with negative effects also reported in the Emerging Markets ARV business and…
• Regulatory RiskImportance 47 · Surprise 60
  A February 2026 fire at Viatris’ oral solid-dose manufacturing facility in Nashik, India temporarily suspended manufacturing. After a May 2026 FDA inspection produced Form 483 observations, Viatris began a…
• Product Launch and TransitionImportance 46 · Surprise 42
  Viatris’ constant-currency net sales increased 3% in the first six months of 2026, supported by approximately $171.8 million of new product sales, primarily in Developed Markets, and $60.7 million of net base business…
• Operating Cash Flow TrendsImportance 42 · Surprise 14
  Net cash provided by operating activities was $770.1 million for the six months ended June 30, 2026, up $14.9 million from $755.2 million in the comparable 2025 period. The increase was principally due to higher…
• Capital Return ProgramImportance 38 · Surprise 24
  Viatris’ board-authorized share repurchase program permits up to $2.0 billion of common-stock repurchases and has no expiration date. During the three and six months ended June 30, 2026, the company repurchased…
• Competition and Pricing PressureImportance 37 · Surprise 42
  Viatris operates in a highly competitive pharmaceutical market where additional generic entrants generally reduce affected-product volume and pricing, especially after periods of market exclusivity. Generic entry for…
• Capital Expenditure PlanImportance 24 · Surprise 14
  Viatris spent approximately $92.7 million on capital expenditures for equipment and facilities during the six months ended June 30, 2026, compared with $95.5 million in the prior-year period. Net cash from investing…

Earnings call · 2026-08-06

• Guidance and OutlookImportance 62 · Surprise 68
  Viatris raised the midpoint of its 2026 guidance ranges for total revenue, adjusted EBITDA and adjusted EPS. The revised midpoints imply approximately 2% operational revenue growth, 5% adjusted EBITDA growth and 7%…
• Capital Return ProgramImportance 52 · Surprise 42
  Through early August, Viatris had deployed approximately $1.4 billion of capital under its balanced allocation strategy. Dividends and share repurchases returned approximately $550 million to shareholders, including…
• Operating Expense TrendsImportance 50 · Surprise 58
  Operating expenses declined as a percentage of revenue in the second quarter. Management attributed the improvement to SG&A discipline and savings from the enterprise-wide strategic review. R&D spending remained in…
• Revenue Performance and MixImportance 49 · Surprise 32
  Second-quarter total revenue was $3.8 billion, up 3.5% operationally year over year. Developed-markets sales rose 2%, including 1% growth in North America and 2% growth in Europe, while emerging-markets sales declined…
• Outstanding IndebtednessImportance 46 · Surprise 42
  Viatris repaid approximately $900 million of debt that matured in June and refinanced the remaining balance. Gross leverage ended the quarter at approximately 2.9x. That ratio was below the midpoint of the company’s…
• Distribution Channels ExpansionImportance 46 · Surprise 56
  Viatris expanded its commercial capabilities in Greater China across e-commerce, retail and hospital channels. E-commerce represented roughly 10% to 15% of the China business and grew 36% year over year in the quarter,…
• Regulatory Approval MilestonesImportance 41 · Surprise 60
  Viatris received U.S. approval for Gwyn Lo, a once-weekly low-dose estrogen transdermal contraceptive patch, and expects to launch it later this year. Fast-acting meloxicam remains under FDA review with anticipated…
• Acquisition / Partnership / DivestitureImportance 40 · Surprise 42
  Viatris agreed to sell its global product rights for Tyrvaya as part of a strategic shift away from eye care. The transaction is expected to close in the second half of 2026, subject to customary closing conditions.…
• Estradiol Capacity ExpansionImportance 40 · Surprise 42
  Demand for Viatris’s estradiol hormone-replacement patches increased sharply after the FDA removed a black-box warning at the end of 2025. Management said the Vermont facility produces next-generation transdermal…
• Hormonal Patch DemandImportance 40 · Surprise 42
  Demand for estradiol patches used in hormone replacement therapy has increased sharply over the past year, primarily because the FDA removed a black-box warning and, to a lesser extent, because GLP-1 use affects…
• Nashik Manufacturing DisruptionsImportance 40 · Surprise 42
  The Nashik manufacturing facility experienced a first-quarter fire and May 2026 FDA inspection observations, prompting a comprehensive remediation plan and intermittent manufacturing disruptions. Management expects the…
• Strategic Review and DivestitureImportance 40 · Surprise 42
  Viatris is executing an enterprise-wide strategic review intended to redirect capital, talent, and resources toward higher-growth opportunities. The company is delivering previously committed savings while reinvesting…
• Greater China Revenue GrowthImportance 36 · Surprise 40
  Greater China revenue increased 16% year over year in the quarter, supported by cardiovascular products, aging-population demand and investments in selling, marketing, e-commerce and retail capabilities. Growth…
• Gross Margin DriversImportance 31 · Surprise 32
  Adjusted gross margin was 57.5% in the second quarter, nearly 1 percentage point above the prior year. Greater China’s strong performance increased margin contribution during the quarter. North American generics also…
• Manufacturing and CapacityImportance 31 · Surprise 42
  Viatris operates 26 manufacturing facilities globally and is increasing capacity at its Vermont site to address unusually strong estradiol-patch demand. Management is also considering external manufacturing resources…
• Clinical Trial Enrollment StrategyImportance 31 · Surprise 42
  Management is allowing the sizable clinical study to continue enrolling rather than stopping early, citing the substantial time, energy, and money already invested. The company expects continued enrollment to generate…
• Free Cash Flow and LiquidityImportance 30 · Surprise 40
  Viatris generated $329 million of second-quarter free cash flow, including transaction and restructuring-related costs and taxes. Excluding those items, free cash flow was $449 million, with the year-over-year…
• Competition and Market ShareImportance 29 · Surprise 24
  In North America, complex generics, transdermal products and Breyna supported growth, while management expects additional competition affecting Breyna and Wixela in the second half. Established brands in North America…
• Trade Policy and TariffsImportance 23 · Surprise 24
  Management said the U.S. administration had not yet released official details on potential tariffs affecting generic drugs. Viatris currently operates eight manufacturing, R&D, and distribution sites in the United…

8-K · 2026-08-06

• Free Cash Flow and LiquidityImportance 75 · Surprise 60
  Viatris estimated free cash flow excluding transaction-related and restructuring-related costs of $1,950 million to $2,350 million. The company estimated transaction-related and restructuring-related costs at…
• Acquisition / Partnership / DivestitureImportance 71 · Surprise 60
  Viatris signed a definitive agreement in August 2026 to sell the global Tyrvaya product rights to Harrow for $30 million upfront and up to $70 million in commercial contingent milestone payments. It completed the sale…
• Net Loss and Tyrvaya ChargeImportance 64 · Surprise 82
  Second-quarter U.S. GAAP net loss was $118.8 million, compared with a $4.6 million net loss in second-quarter 2025. The loss included a $177.8 million non-cash charge for the planned sale of Tyrvaya product rights and…
• Debt Refinancing ExposureImportance 64 · Surprise 42
  Viatris repaid approximately $900 million of debt that matured in June 2026. It refinanced the remaining balance through a €650 million aggregate principal amount public offering of euro-denominated senior notes…
• Operating Cash Flow and Free Cash FlowImportance 63 · Surprise 64
  Second-quarter operating cash flow increased 74% to $381.8 million from $219.7 million. Free cash flow increased 97% to $329.0 million, or $449 million excluding $120 million of transaction-related and…
• Operating Expense TrendsImportance 60 · Surprise 74
  Second-quarter R&D expense increased 13% to $248.3 million from $218.8 million, with adjusted R&D rising to $242.0 million from $211.2 million. Reported SG&A increased 22% to $1,134.5 million from $928.7 million,…
• Supply Chain DisruptionsImportance 46 · Surprise 42
  Viatris reported intermittent manufacturing disruptions at its oral solid dose facility in Nashik, India, following FDA Form 483 observations and a February fire-related suspension. Production has resumed, but…
• Capital Return ProgramImportance 44 · Surprise 24
  Through August 5, 2026, Viatris returned approximately $550 million to shareholders. Share repurchases accounted for approximately $270 million at a weighted-average purchase price of $16.42 per share. Approximately…
• Adjusted EBITDA PerformanceImportance 44 · Surprise 40
  Viatris reported quarterly adjusted EBITDA of $1,154.6 million for the quarter ended September 30, 2025, $1,003.1 million for December 31, 2025, $1,049.5 million for March 31, 2026, and $1,188.3 million for June 30,…
• Product Launch and TransitionImportance 40 · Surprise 42
  Viatris generated approximately $101 million in new product revenues during the second quarter and approximately $172 million year to date. New product revenues include products launched in 2026 and carryover effects…
• Regulatory Remediation CostsImportance 40 · Surprise 42
  In May 2026, the U.S. FDA inspected Viatris's oral solid dose manufacturing facility in Nashik, India, and issued Form 483 observations. Viatris initiated a comprehensive remediation plan supported by independent…
• Outstanding IndebtednessImportance 37 · Surprise 6
  Viatris reported long-term debt, including the current portion, of $13,348.6 million at June 30, 2026. After deducting $423.7 million of net premiums and adding $23.1 million of deferred financing fees, total debt at…
• FX / Currency HeadwindsImportance 32 · Surprise 24
  Foreign exchange reduced second-quarter 2026 total revenues by $49.3 million and six-month total revenues by $211.1 million versus reported results. The six-month currency impact included unfavorable effects of $148.5…
• Gross Margin DriversImportance 31 · Surprise 32
  Second-quarter U.S. GAAP gross profit increased 9% to $1,456.5 million from $1,332.9 million, and U.S. GAAP gross margin expanded to 38.8% from 37.2%. Adjusted gross profit increased 6% to $2,158.9 million, while…
• Revenue Performance and MixImportance 31 · Surprise 32
  Second-quarter total revenues increased 3.5% operationally, driven primarily by new product sales in Developed Markets and strong growth in Greater China. Greater China net sales rose 16% operationally to $685.2…
• Product / Drug Pipeline ProgressImportance 31 · Surprise 42
  The FDA approved Gwyn Lo (norelgestromin and ethinyl estradiol transdermal system), a new combined hormonal contraceptive patch with low-dose estrogen. Viatris reported positive top-line Phase 3 results for VR-205, its…
• Distribution Channels and PartnershipsImportance 31 · Surprise 42
  Viatris signed a distribution agreement with Accord Healthcare to commercialize filgrastim, ustekinumab and teriparatide biosimilars in France. The company also entered a co-promotion partnership with Idorsia for…
• Regulatory Approval MilestonesImportance 31 · Surprise 42
  The U.S. FDA approved Gwyn Lo, a low-dose estrogen combined hormonal contraceptive patch, in July 2026, with commercial availability expected later in the year. In June, the FDA approved Viatris's generic ferric…